Abstract:It has been 18 years since the concept of ERAS (enhanced recovery after surgery)been proposed, and there has been 10 years experience since it was first applicated in China. Not only it was shortened in hospital stay but also reduction in surgical stress, pain and complications. All of which leads to the patients' fast recovery. ERAS is an integrated innovation, which involves multidisciplinary, including hospital administration and etc. The traditional clinical pathway has to be changed. Additional investigation has to be conducted on postoperative ileus and the recovery of intestinal function. Great effort should been made to the clinical applications of ERAS as well.

Abstract:The Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) have issued the Eighth Edition of TNM staging system manual in October 2016. The updated version made evidence-based, prominent revisions in cancer stage classification system. Specifically, the old TNM staging system based on post-operative pathological examination was replaced by a more sophisticated staging system including clinical staging (cTNM), pathological staging (pTNM), and neo-adjuvant post-treatment staging (ypTNM). These revisions help oncologists and other clinicians better determine the stage of gastric cancer patients according to their conditions and treatments. Consequentially, appropriate individualized anti-cancer treatment could be made possible for each patient. Also, the Eighth Edition revised the guidance in staging gastroesophageal junction cancer and cardia cancer. Another update is N3a and N3b, separated from N3, work as two independent groups in staging system. Comparing to the Seventh Edition, some adjustment was made in sub-classifying patients of stage III. The usefulness and appropriateness of the new updates need clinical validation around the world. Although a risk prediction model incorporating the recent advancement of molecular biology has not been developed as expected, the Eighth Edition provides a useful tool for clinicians in the transition to precision treatment for gastric cancer.